The International Society of Pharmaceutical Engineering (ISPE), the world’s largest not-for-profit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical life cycle, has announced the results of its 2017–2018 International Board of Directors election, revealing a slate of strategic leaders who represent a variety of pharmaceutical industry sectors. The Board is responsible for the governance and strategic direction of the Society and will assume their elected positions at the ISPE 2017 Annual Meeting & Expo, from 29 October to1 November in San Diego, California, USA.
“I am looking forward to collaborating with the incoming International Board of Directors to further the organization and advance the Society mission and vision,” said John Bournas, ISPE CEO and President. “The new leadership team will not only provide invaluable guidance with regards to our strategic direction and efforts to support the bio pharmaceutical manufacturing industry, but will continue the organization’s further globalization.”
Following pharmaceutical industry leaders have been elected to positions on the 2017–2018 ISPE International Board of Directors: Chair: Timothy P. Howard, CPIP, PE, Vice President, Commissioning Agents, Inc. Vice Chair: James Breen Jr., PE, Lead, Biologics Expansion, Janssen Pharmaceuticals; Treasurer: Frances (Fran) M. Zipp, President & CEO, Lachman Consultant Services, Inc.; Secretary: Thomas Hartman, Vice President of GMP Operations, Biopharm CMC, GlaxoSmithKline.
Re-elected director: The following individual served in 2015–2017 and has been re-elected to a second two-year term: Tony (Antonio) Crincoli, PE, Executive Director and Head of Global Engineering Services, Bristol-Myers Squibb.
New directors: Flemming Dahl, Senior Vice President, Novo Nordisk A/S; Kelly Keen, Project Portfolio Management, BPm, F Hoffman-La Roche Ltd; Alice Redmond, PhD, Vice President, European Operations, Commissioning Agents, Inc; Michael Rutherford, Consultant - Laboratory and Quality Systems, Eli Lilly and Company.
In addition to those named above, the following directors were elected in 2016 to serve a two-year term and will continue their service on the Board: Joanne R. Barrick, RPh, Advisor in Global Validation Support, Eli Lilly and Company; Peter S. Carbone, Vice President, Quality Head Solids Americas and Special Technologies, Novartis; Christine M.V. Moore, PhD, Global Head and Executive Director, GRACS CMC – Policy, Merck; Fatma Taman, Chief Technical Officer, MS Pharma; Jörg Zimmermann, Vice President of Vetter Development Services, Vetter Pharma Fertigung GmbH&Co KG.